Medicine composition for treating myelodysplastic syndrome and application thereof

Abstract

The invention provides a medicine for treating myelodysplastic syndrome. The medicine is prepared from the following components of 10 to 40 parts of poria cocos, 10 to 40 parts of radix astragali seuhedysari, 10 to 40 parts of bulbus fritillariae thunbergii, 10 to 35 parts of bighead atractylodes rhizome, 10 to 35 parts of cortex moutan, 10 to 35 parts of radix codcnopsitis pilosulas, 10 to 35 parts of fructus taxi wallichianae, 10 to 35 parts of semen armeniacae amarae, 10 to 35 parts of radix adenophorae, 10 to 35 parts of radix rehmanniae, and 3 to 15 parts of liquorice root. The medicinehas the advantages that by scientifically compounding the traditional Chinese herbs, the traditional Chinese medicine is prepared by repeated verification of clinical experiment; the medicine can reach good treatment effect on the myelodysplastic syndrome (refractory anemia); when the medicine is used together with Western medicines of thalidomide and the like, a patient who relies on blood transfusion for a long time can get rid of blood transfusion, or the blood source is greatly reduced, the recurrence is prevented, the progress of disease is blocked, the living quality is improved, and thepatient can healthily survive for a long time; the toxic and side effects are low, the treatment cost is low, and the medicine can be easily accepted by the patient.

Description

technical field [0001] The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine prescription or pharmaceutical composition for treating myelodysplastic syndrome (refractory anemia) and its application. Background technique [0002] Myelodysplastic syndrome (refractory anemia) (myelodysplastic syndromes, MDS) is a group of malignant clonal diseases of hematopoietic stem cells / progenitor cells [Barzi A, Sekeres MA. Myelodysplastic syndromes: apractical approach to diagnosis and treatment. Cleve Clin J Med ,2010,77:37-44.], is a common malignant tumor blood disease in the elderly, with a high incidence rate, the incidence rate of people over 70 years old is 20~35 / 100,000, and it has become a malignant disease that seriously threatens human health. There are about 70,000 new cases in my country every year. With the aging population in our country, the incidence rate will gradually increase. The pathogenesis of this dise...

AI Technical Summary

Problems solved by technology

The treatment ideas of these drugs are implemented in the specific treatment plan or medication strategy of the disease, but there are still shortcomings such as long treatment course, slow effect, ineffective effect, and not easy to be accepted by patients.

Throughout the various reports of TCM treatment of myelodysplastic syndrome (refractory anemia), most of the therapeutic effects are difficult to reach the complete remission and partial remission in the curative effect evaluation criteria of the International Working Group (MDS-IWG) for myelodysplastic syndrome. ease